...
首页> 外文期刊>Nuclear Medicine Communications >Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin
【24h】

Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin

机译:甲状腺乳头状癌患者低碘放射性消融的长期结果及术后非刺激性甲状腺球蛋白的预测价值

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AimThis study evaluated the long-term results of ablation with low iodine-131 (131I) activity in patients with papillary thyroid carcinoma (PTC) with a lower risk of recurrence and who remained with nonstimulated thyroglobulin (Tg) of at least 0.3ng/ml after total thyroidectomy.MethodsThis was a prospective study including 119 patients with PTC (except for microcarcinoma restricted to the thyroid and tumor with extensive extrathyroidal extension, aggressive histology, extensive lymph node involvement, or known residual disease). After thyroidectomy, all patients had nonstimulated Tg of at least 0.3ng/ml (range: 0.3-8.5ng/ml). The patients were treated with low 131I activity (30 or 50mCi).ResultsPost-therapy whole-body scanning showed ectopic uptake in two patients. When evaluated 12 months after ablation, nonstimulated Tg up to 0.2ng/ml with negative antithyroglobulin antibodies and neck ultrasonography, defined as excellent response to initial therapy, was achieved in 92 patients (77.3%). Only one patient had persistent structural disease. During follow-up, 3/118 patients (2.5%) developed structural recurrence. In the last assessment, 102/115 patients who were not subjected to any additional therapy had nonstimulated Tg up to 0.2ng/ml, negative antithyroglobulin antibodies, and ultrasonography with no anomalies. No death occurred because of the tumor.ConclusionsPostoperative nonstimulated Tg up to 2ng/ml had a negative predictive value of 98% for recurrent or persistent structural disease. In patients with PTC who have a lower risk of recurrence and who remain with nonstimulated Tg of at least 0.3ng/ml after total thyroidectomy, Tg up to 2ng/ml can be used as a criterion for ablation with low 131I activity. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
机译:目的这项研究评估了低碘-131(131I)活性消融治疗甲状腺乳头状癌(PTC)且复发风险较低且甲状腺球蛋白(Tg)至少为0.3ng / ml的患者的长期结果方法这是一项前瞻性研究,包括119例PTC患者(除了限于甲状腺的微癌和甲状腺外广泛扩展,侵袭性组织学,广泛淋巴结受累或已知残留疾病的肿瘤)。甲状腺切除术后,所有患者的非刺激性Tg至少为0.3ng / ml(范围:0.3-8.5ng / ml)。结果患者的131I活性低(30或50mCi)。结果治疗后的全身扫描显示两名患者接受了异位摄取。在消融后12个月进行评估时,有92例患者(77.3%)达到了抗刺激性甲状腺球蛋白抗体阴性的非刺激性Tg高达0.2ng / ml,并且颈部超声检查被定义为对初始治疗的良好反应。只有一名患者患有持续性结构疾病。在随访期间,3/118例患者(2.5%)发展为结构性复发。在上一次评估中,没有接受任何其他治疗的102/115例患者的未刺激Tg高达0.2ng / ml,抗甲状腺球蛋白抗体阴性,并且超声检查无异常。结论术后无刺激Tg达2ng / ml对复发性或持续性结构性疾病的阴性预测值为98%。对于PTC复发风险较低且在全甲状腺切除术后未刺激的Tg至少保持在0.3ng / ml的PTC患者中,Tg最高为2ng / ml可以作为131I活性低的消融标准。版权所有(C)2016 Wolters Kluwer Health,Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号